URSODIOL IN THE LONG-TERM TREATMENT OF CHRONIC HEPATITIS - A DOUBLE-BLIND MULTICENTER CLINICAL-TRIAL

被引:59
作者
BELLENTANI, S
PODDA, M
TIRIBELLI, C
CALLEA, F
MARAZZI, C
SODDE, M
MERLINI, R
BATEZZATI, PM
CROSIGNANI, A
ZUIN, M
MANENTI, F
机构
[1] UNIV MILAN,FONDO STUDIO FEGATO,MILAN,ITALY
[2] UNIV MILAN,CATTEDRA MED INTERNA,MILAN,ITALY
[3] UNIV TRIESTE,CATTEDRA BIOCHIM CLIN,TRIESTE,ITALY
[4] IST GIANNINA GASLINI,I-16148 GENOA,ITALY
[5] UNIV MODENA,CATTEDRA GASTROENTEROL,MODENA,ITALY
关键词
URSODEOXYCHOLIC ACID; URSODIOL; CHRONIC HEPATITIS; CLINICAL TRIAL;
D O I
10.1016/S0168-8278(05)80558-6
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Ursodeoxycholic acid (UDCA or ursodiol) administration has been associated with a reduction of serum liver enzymes in patients with chronic liver disease and with improvement of liver histology in patients with primary biliary cirrhosis. To establish the potential therapeutic efficacy of ursodiol in chronic hepatitis, serum biochemistry and liver histology were investigated in a multicenter, double-blind placebo controlled clinical trial. Sixty patients with non-cholestatic chronic active (mild or severe) hepatitis, mainly of viral (virus C) etiology and almost completely asymptomatic, were enrolled in 3 centers: 29 were assigned to receive placebo and 31 UDCA (600 mg/day) for 1 year. Demographic, biochemical, virological and histological features were balanced between the 2 groups at the entrance into the study. Fiftysix patients (34 males, 22 females; 19 with cirrhosis; 5 HBsAg-positive; 45 anti-HCV positive) were included in the final analysis. Compliance was checked by measuring UDCA levels at the 3 follow-up visits (3, 6 and 12 months). Liver biopsy was performed at the beginning and at the end of treatment and was evaluated blindly by our pathologist (F.C.). Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gammaglutamyltransferase (GGT) levels were significantly reduced by 25% from baseline values during treatment with ursodiol but not with placebo. The efficacy of UDCA in lowering serum AST and ALT was more pronounced in the presence of cirrhosis. The semiquantitative liver histological score used remained substantially unchanged after treatment and no differences between placebo and UDCA were found for portal or periportal necrosis or inflammation, intralobular degeneration, cholestasis or fibrosis. We conclude that UDCA administration for 1 year in patients with post-viral, non-cholestatic chronic active hepatitis might have an ancillary role in reducing cellular injury, but does not influence histological activity.
引用
收藏
页码:459 / 464
页数:6
相关论文
共 29 条
[1]  
AKASHI Y, 1987, CLIN CHIM ACTA, V2, P199
[2]   EFFECT OF URSODEOXYCHOLIC ACID TREATMENT ON ALANINE AMINOTRANSFERASE AND GAMMA-GLUTAMYL-TRANSPEPTIDASE SERUM LEVELS IN PATIENTS WITH HYPERTRANSAMINASEMIA - RESULTS FROM A DOUBLE-BLIND CONTROLLED TRIAL [J].
BELLENTANI, S ;
TABARRONI, G ;
BARCHI, T ;
FERRETTI, I ;
FRATTI, N ;
VILLA, E ;
MANENTI, F .
JOURNAL OF HEPATOLOGY, 1989, 8 (01) :7-12
[3]  
CAPOCACCIA L, 1983, BILE ACIDS GASTROENT, P209
[4]   URSODEOXYCHOLIC ACID FOR PRIMARY SCLEROSING CHOLANGITIS [J].
CHAZOUILLERES, O ;
POUPON, R ;
CAPRON, JP ;
METMAN, EH ;
DHUMEAUX, D ;
AMOURETTI, M ;
COUZIGOU, P ;
LABAYLE, D ;
TRINCHET, JC .
JOURNAL OF HEPATOLOGY, 1990, 11 (01) :120-123
[5]  
COMBES B, 1991, HEPATOLOGY, V14, pA91
[6]   EFFECTS OF URSODEOXYCHOLIC ACID ON SERUM LIVER-ENZYMES AND BILE-ACID METABOLISM IN CHRONIC ACTIVE HEPATITIS - A DOSE-RESPONSE STUDY [J].
CROSIGNANI, A ;
BATTEZZATI, PM ;
SETCHELL, KDR ;
CAMISASCA, M ;
BERTOLINI, E ;
RODA, A ;
ZUIN, M ;
PODDA, M .
HEPATOLOGY, 1991, 13 (02) :339-344
[7]  
DAVID R, 1985, Z GASTROENTEROL, V23, P420
[8]  
DICKSON ER, 1989, HEPATOLOGY, V10, P8
[9]  
FISHER MM, 1986, GASTROENTEROLOGY, V90, P1725
[10]   URSODEOXYCHOLATE REDUCES HEPATOTOXICITY OF BILE-SALTS IN PRIMARY HUMAN HEPATOCYTES [J].
GALLE, PR ;
THEILMANN, L ;
RAEDSCH, R ;
OTTO, G ;
STIEHL, A .
HEPATOLOGY, 1990, 12 (03) :486-491